Skip to main content
Premium Trial:

Request an Annual Quote

GeneFormatics Raises $15M in Venture Capital

NEW YORK, Oct 5 – Proteomics company GeneFormatics said Thursday it raised $15 million in a series B round of financing.

Perseus-Soros BioPharmaceutical Fund led the round. Merrill Lynch Ventures, OrbiMed Advisors, GeneChem Management and previous investors, Burrill & Company, Inglewood Ventures, and Moss Forest Venture also participated in the financing round.

The San Diego-based company uses technology originally developed by the Scripps Research Institute to predict a protein’s function by uncovering its structure.

GeneFormatics, which has research agreements with Bristol-Myers Squibb and Schering-Plough Research Institute, said it would use the proceeds from the financing to expand its library of Fuzzy Functional Forms, which is used to mine protein sequences for function. The company said it would also use the money to improve its platforms and license outside technologies.

In additon, the company is working on completing its protein structure/function database, which is based on publicly available protein sequences.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.